Scios Natrecor
Executive Summary
Bayer terminates 1998 agreement to market acute congestive heart failure therapy Natrecor (nesiritide), which received a "not approvable" letter from FDA in April ("The Pink Sheet" May 3, In Brief). Scios says it will seek a new partner to develop and market the product